Editas Medicine Announces Third Quarter 2021 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Editas Medicine (EDIT) Tops Q3 EPS by 25c; Cash and Cash Equivalents of $657.0M
November 8, 2021 7:13 AM ESTEditas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.57), $0.25 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $4.78 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More